API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Royalty Pharma will acquire Minerva’s royalty interest in seltorexant. Seltorexant is currently in Phase 3 development for the treatment of major depressive disorder (MDD) with insomnia symptoms by Janssen Pharmaceutica, N.V., a subsidiary of Johnson & Johnson.
Lead Product(s): Seltorexant
Therapeutic Area: Psychiatry/Psychology Product Name: MIN-202
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Royalty Pharma
Deal Size: $155.0 million Upfront Cash: $60.0 million
Deal Type: Acquisition January 19, 2021
Details:
Minerva Neuroscienceshas exercised its right to opt out of its agreement with Janssen Pharmaceutica future development of seltorexant. As a result, Minerva will now collect a royalty on worldwide sales of seltorexant in all indications.
Lead Product(s): Seltorexant
Therapeutic Area: Sleep Product Name: MIN-202
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Johnson & Johnson Innovative Medicine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 01, 2020